Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + paclitaxel + bevacizumab
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Pembrolizumab + paclitaxel + bevacizumab is a drug combination used in oncology, specifically for the first-line treatment of persistent, recurrent, or metastatic cervical cancer. Pembrolizumab is a monoclonal antibody targeting programmed cell death protein 1 (PD-1), acting as an immune checkpoint inhibitor to enhance antitumor immune response. Paclitaxel is a small molecule antineoplastic agent that stabilizes microtubules and inhibits cell division. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), reducing tumor vascularization. The combination is approved and supported by clinical trial evidence to improve overall survival and progression-free survival compared to chemotherapy alone, particularly in tumors expressing PD-L1[1][2][4][6].
- Brand names
- Keytruda + paclitaxel + Avastin
- Other names
- pembrolizumab + paclitaxel + bevacizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on pembrolizumab + paclitaxel + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + paclitaxel + bevacizumab.